These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2767860)

  • 1. Exclusion of clinically atypical or microbiologically mixed diarrhoeal episodes from outcome events in a field trial of oral cholera vaccines.
    Clemens JD; Stanton BF; Harris JR; Chakraborty J; Sack DA; Rao MR; Ahmed F; Ansaruzzaman M; Yunus MD; Svennerholm AM
    Int J Epidemiol; 1989 Jun; 18(2):440-5. PubMed ID: 2767860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. II. Field evaluation of cross-protection against other members of the Vibrionaceae family.
    Clemens JD; Harris JR; Kay BA; Chakraborty J; Sack DA; Ansaruzzaman M; Rahman R; Stanton BF; Khan MU; Khan MR
    Vaccine; 1989 Apr; 7(2):117-20. PubMed ID: 2665350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Field trial of oral cholera vaccines in Bangladesh.
    Clemens JD; Sack DA; Harris JR; Chakraborty J; Khan MR; Stanton BF; Kay BA; Khan MU; Yunus M; Atkinson W
    Lancet; 1986 Jul; 2(8499):124-7. PubMed ID: 2873397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera.
    Clemens JD; Sack DA; Harris JR; Chakraborty J; Khan MR; Stanton BF; Ali M; Ahmed F; Yunus M; Kay BA
    Lancet; 1988 Jun; 1(8599):1375-9. PubMed ID: 2898052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up.
    Clemens JD; Harris JR; Sack DA; Chakraborty J; Ahmed F; Stanton BF; Khan MU; Kay BA; Huda N; Khan MR
    J Infect Dis; 1988 Jul; 158(1):60-9. PubMed ID: 3392421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.
    Clemens JD; Sack DA; Harris JR; Van Loon F; Chakraborty J; Ahmed F; Rao MR; Khan MR; Yunus M; Huda N
    Lancet; 1990 Feb; 335(8684):270-3. PubMed ID: 1967730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area.
    Clemens JD; Sack DA; Rao MR; Chakraborty J; Khan MR; Kay B; Ahmed F; Banik AK; van Loon FP; Yunus M
    J Infect Dis; 1992 Nov; 166(5):1029-34. PubMed ID: 1402014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
    Im J; Islam MT; Ahmmed F; Kim DR; Chon Y; Zaman K; Khan AI; Ali M; Marks F; Qadri F; Clemens JD
    PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007179. PubMed ID: 30870416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
    Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
    Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.
    Clemens JD; Sack DA; Harris JR; Chakraborty J; Neogy PK; Stanton B; Huda N; Khan MU; Kay BA; Khan MR
    J Infect Dis; 1988 Aug; 158(2):372-7. PubMed ID: 3042876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.
    Bhattacharya SK; Sur D; Ali M; Kanungo S; You YA; Manna B; Sah B; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Dhingra MS; Donner A; Nair GB; Lopez AL; Wierzba TF; Clemens JD
    Lancet Infect Dis; 2013 Dec; 13(12):1050-6. PubMed ID: 24140390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up.
    van Loon FP; Clemens JD; Chakraborty J; Rao MR; Kay BA; Sack DA; Yunus M; Ali M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Feb; 14(2):162-6. PubMed ID: 8852414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh.
    Clemens J; Sack D; Rao M; Chakraborty J; Kay B; Ahmed F; Khan MR; van Loon FP; Svennerholm AM; Holmgren J
    Int J Epidemiol; 1993 Aug; 22(4):724-30. PubMed ID: 8225749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
    Taylor DN; Cárdenas V; Sanchez JL; Bégué RE; Gilman R; Bautista C; Perez J; Puga R; Gaillour A; Meza R; Echeverria P; Sadoff J
    J Infect Dis; 2000 May; 181(5):1667-73. PubMed ID: 10823767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines.
    Clemens JD; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; van Loon F; Khan MR; Yunis M; Huda S
    Vaccine; 1990 Oct; 8(5):469-72. PubMed ID: 2251873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
    Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
    Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.
    Peltola H; Siitonen A; Kyrönseppä H; Simula I; Mattila L; Oksanen P; Kataja MJ; Cadoz M
    Lancet; 1991 Nov; 338(8778):1285-9. PubMed ID: 1682684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.